CollPlant Biotechnologies Ltd: 5%+ holders

CollPlant Biotechnologies Ltd has 7 Schedule 13D or 13G filings on record since 2025-09-30. 2 holders' latest filing reports 5% or more of ordinary shares, par value nis 1.5 per share. Each figure below is the holder's own, as filed, with the filing linked.

Stated intent

Intent stated in Item 4 Loewenbaum Lilian S.

On October 20, 2025, the Reporting Persons delivered a letter to the Board of Directors of the Issuer (the "Board") requesting the appointment of Nachum Shamir as Chairman in the immediate future and requesting consideration of adding other qualified individuals to the board.From Item 4 of the SCHEDULE 13D/A filed 2025-11-07

Intent stated in Item 4 Loewenbaum Lilian S.

On October 20, 2024, the Reporting Persons delivered a letter to the Board of Directors of the Issuer (the "Board") requesting the appointment of Nachum Shamir as Chairman in the immediate future and requesting consideration of adding other qualified individuals to the board.From Item 4 of the SCHEDULE 13D/A filed 2025-10-20

Holders

Purpose of Transaction (Item 4)

Loewenbaum Lilian S.

On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with the Issuer for the purchase of 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 Ordinary Shares (the "Series A Warrants"), and Series B Warrants to purchase 3,529,412 Ordinary Shares (the "Series B Warrants" and, together with the Series A Warrants, the "Warrants"). The transaction was completed on July 6, 2026. The Series A Warrants have an exercise price of $0.34 per share and are exercisable as of July 29, 2026, the date of shareholder approval (the "Shareholder Approval Date"). The Series A Warrants expire on July 16, 2028. The Series B Warrants have an exercise price of $0.34 per share and are exercisable as of the Shareholder Approval Date. The Series B Warrants expire on July 16, 2031. The Loewenbaum 1992 Trust is only permitted to exercise the Warrants up to a beneficial ownership limitation of 24.99% (the "Beneficial Ownership Limitation") which limitation is based on holdings of the other Reporting Persons. Effective August 20, 2026, The Lowenbaum 1992 Trust and the Issuer memorialized a transfer of funds whereby The Lowenbaum 1992 Trust transferred funds in the amount of the aggregate exercise price of the Series B Warrants. No Warrants were exercised, and the funds are held in abeyance until further notice from The Lowenbaum 1992 Trust. The acquisitions of Ordinary Shares and Warrants by the Reporting Persons was for investment purposes. The …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-21; the filing has the rest

Ami Sagy

The Reporting Person is filing this Amendment No. 4 to Schedule 13D ("Amendment No. 4") to report his sale of 140,000 Ordinary Shares during the period from October 16, 2025 through November 19, 2025. Furthermore, since he last filed Amendment No. 3 to Schedule 13D on November 5, 2019, the Reporting Person's beneficial ownership has decreased materially. The Reporting Person holds the Ordinary Shares reported herein for investment purposes only. The Reporting Person may, from time to time, based on various factors, acquire additional Ordinary Shares of the Issuer or sell Ordinary Shares, on the open market or in privately negotiated transactions. Except as described above, as of the filing of this Amendment No. 4, the Reporting Person does not have any definitive plans or proposals which relate to or would result in any of the following: (a) the acquisition by the Reporting Person of additional Ordinary Shares, or the disposition of Ordinary Shares that he holds; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) a change in the present board of directors or management of the Issuer, including any plan or proposal to change the number or term of directors or to fill any existing vacancies on the board; (e) a material change in the present capitalization or dividend policy of the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-28; the filing has the rest

Timeline

CollPlant Biotechnologies Ltd: every filing and event

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes